# ABBOTINDIA (ABBOTINDIA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/abbotindia

## Current market snapshot

- Exchange: NSE
- Country: India
- Price: ₹27,335
- Change: +5.50%
- As of: 2026-09-18
- 1D return: +5.25%
- 5D return: +7.96%
- 1M return: +4.40%
- Latest complete quarter: —

## Faxioms Analysis

_As of 2026-09-18_

### Technical Outlook

As of September 18, 2026, ABBOTINDIA's technical stance is mixed, with a daily uptrend conflicting with longer-term bearish signals. The stock's closing price of ₹27,270.0 is above key daily moving averages, including the 20-day EMA (₹26,210.11) and 200-day SMA (₹26,992.05), indicating positive short-term momentum. However, on a weekly and monthly basis, the price is below the Supertrend indicator and key moving averages, suggesting underlying weakness. The nearest support is observed at ₹26,826.56, approximately 1.63% below the current price, while the nearest resistance is at ₹28,521.55, about 4.59% higher. Recent activity includes a "Morning Star" pattern on the daily chart and a "Harami" pattern on the monthly chart, both potentially signaling trend reversals. The stock has experienced significant volume with price movement on September 18, 2026, with a volume ratio of 5.07 and a Z-score of 13.9.

The stock's current position is within the upper half of its 50-day and 252-day trading ranges, with the 50-day range position at 0.56 and the 252-day range position at 0.34. Annualized volatility stands at 23%, and the current drawdown is -24%. The conflicting signals across timeframes suggest a period of consolidation or transition. Key watch conditions include monitoring the price action around the ₹26,826.56 support level and the ₹28,521.55 resistance level. A decisive break above resistance could strengthen the daily uptrend, while a fall below support might signal further downside, especially if it coincides with increased selling volume.

- The stock closed at ₹27,270.0 on September 18, 2026.
- Daily trend is bullish, with price above key moving averages (EMA 20, SMA 200).
- Weekly and monthly trends show bearish signals, with price below Supertrend and key moving averages.
- Nearest support is at ₹26,826.56 (1.63% below current price).
- Nearest resistance is at ₹28,521.55 (4.59% above current price).
- Significant volume anomaly (ratio 5.07) observed on September 18, 2026.

- Harami
- Morning Star
- Inside Bar
- Doji
- Outside Bar

### News Context

Abbott India Ltd's stock experienced a third consecutive day of gains, closing at ₹26,155 on September 15, 2026, marking a 2.37% increase for that day. Despite this recent upward trend, the stock has seen a 15.44% decline over the past year. This performance contrasts with the broader market, as the NIFTY index rose 7.58% and the Nifty Pharma index increased by 18.39% during the same one-year period. Separately, a report on September 14, 2026, highlighted intensifying regulatory scrutiny in India's Fast-Moving Consumer Goods (FMCG) sector concerning misleading product claims. This regulatory push, which includes proposed front-of-pack warning labels for unhealthy packaged foods, is prompting companies to increase investments in compliance and quality checks.

- Abbott India Ltd stock traded at ₹26,155, up 2.37% on September 15, 2026.
- The stock has declined 15.44% in the last year.
- The NIFTY index increased 7.58% and the Nifty Pharma index rose 18.39% in the last year.
- Indian regulators are increasing scrutiny over misleading food product claims, as reported on September 14, 2026.

- Abbott India Ltd rises for third straight session
- What’s in a word? For India's FMCG brands, it's increasingly everything

### What Changed

As of September 18, 2026, Abbott India's stock has seen an increase in price. The previous price recorded was ₹25,910.0, and the current price is ₹27,270.0. No new filings or news developments were reported for the period.

The company, commonly known as Abbott India, continues to be listed on the NSE. The recent price movement represents a change from the prior recorded price, while other contextual elements remain consistent.

- On 2026-09-18, Abbott India's stock price was ₹27,270.0.
- The stock price on the previous observation date was ₹25,910.0.
- Abbott India is listed on the NSE.
- No new filings or news were reported as of 2026-09-18.

### Official Filings

Abbott India's financial position shows a notable increase in total assets from ₹2,941 crore in March 2019 to ₹3,547 crore in March 2020. This growth is primarily driven by a significant rise in fixed assets, which increased from ₹105 crore to ₹270 crore over the same period, alongside an increase in other assets. Concurrently, total liabilities also grew, with borrowings appearing in March 2020 at ₹175 crore, compared to none in March 2019. The company's reserves saw a substantial increase from ₹1,987 crore to ₹2,410 crore between March 2019 and March 2020. Cash flow from operating activities increased to ₹626 crore in March 2020 from ₹499 crore in March 2019, contributing to a higher free cash flow of ₹611 crore in March 2020. However, net cash flow decreased to ₹8 crore in March 2020 from ₹99 crore in March 2019, impacted by increased cash used in investing activities, which rose to ₹401 crore from ₹257 crore.

In terms of market performance, Abbott India's stock has experienced a decline of 15.44% over the past year, contrasting with the Nifty's 7.58% jump and the Nifty Pharma index's 18.39% rise. Recent news indicates the stock has risen for three consecutive sessions, trading at ₹26,155 as of 12:49 IST on the NSE. Separately, a broader market development highlights increasing regulatory scrutiny on Indian FMCG brands regarding product claims, with proposed front-of-pack warning labels for unhealthy foods, prompting companies to allocate more resources to compliance and quality checks.

- Total assets for Abbott India increased to ₹3,547 crore in March 2020 from ₹2,941 crore in March 2019, driven by growth in fixed and other assets.
- Borrowings were recorded at ₹175 crore in March 2020, a change from zero in March 2019.
- Reserves grew to ₹2,410 crore in March 2020, up from ₹1,987 crore in March 2019.
- Cash flow from operations increased to ₹626 crore in March 2020, supporting a free cash flow of ₹611 crore.
- The stock has declined 15.44% over the last year, underperforming the Nifty Pharma index.

- Abbott India Ltd rises for third straight session
- What’s in a word? For India's FMCG brands, it's increasingly everything

### Fundamentals

Abbott India's recent financial performance shows a consistent upward trend in sales and profitability. For the fiscal year ending March 2024, sales reached ₹5,849 crore, with operating profit at ₹1,453 crore and a net profit of ₹1,201 crore. The operating profit margin (OPM) stood at 25.0% for the same period. Looking ahead, projections indicate continued growth, with estimated sales of ₹6,409 crore for FY25 and ₹6,929 crore for FY26, accompanied by expanding OPM to 26.0% and 27.0% respectively. Earnings per share (EPS) have also shown a strong trajectory, growing from ₹211.93 in FY19 to ₹565.30 in FY24, with further increases projected to ₹665.64 in FY25 and ₹730.39 in FY26.

The company's balance sheet indicates a reduction in borrowings, which decreased from ₹175 crore in March 2020 to ₹83 crore in March 2024. Equity capital has remained stable at ₹21 crore throughout this period, while reserves have grown significantly from ₹2,410 crore in March 2020 to ₹3,678 crore in March 2024. This suggests a strengthening financial position with decreasing reliance on debt. Cash flow from operations has been robust, with ₹1,213 crore generated in FY24, contributing to a healthy free cash flow of ₹1,165 crore in the same year. Key monitoring areas include the increasing trend in Other Assets, which rose from ₹3,275 crore in March 2020 to ₹4,958 crore in March 2024, and the fluctuating Cash from Investing Activity, which saw a significant outflow of ₹416 crore in FY24.

- For the fiscal year ending March 2024, Abbott India reported sales of ₹5,849 crore, operating profit of ₹1,453 crore, and net profit of ₹1,201 crore, with an operating profit margin of 25.0%.
- Projected sales are estimated at ₹6,409 crore for FY25 and ₹6,929 crore for FY26, with operating profit margins expected to increase to 26.0% and 27.0% respectively.
- Earnings Per Share (EPS) grew from ₹211.93 in FY19 to ₹565.30 in FY24, with projections of ₹665.64 for FY25 and ₹730.39 for FY26.
- Borrowings have decreased from ₹175 crore in March 2020 to ₹83 crore in March 2024, while reserves have increased from ₹2,410 crore to ₹3,678 crore over the same period.
- Cash flow from operations was ₹1,213 crore in FY24, supporting a free cash flow of ₹1,165 crore.

### Bull Case

Abbott India's financial performance shows positive trends in cash flow generation and profit growth. The company has demonstrated a consistent increase in its reserves, growing from ₹2,410 crore in March 2020 to ₹1,987 crore in March 2019. Furthermore, its operating cash flow has seen an increase, with Free Cash Flow rising to ₹611 crore in March 2020 from ₹504 crore in March 2019. The company has also achieved a compounded profit growth of 17% over the last five years and 11% on a trailing twelve-month (TTM) basis. While the company has seen an increase in borrowings from ₹0 crore in March 2019 to ₹175 crore in March 2020, its equity capital has remained stable at ₹21 crore, and its reserves have grown significantly.

- Compounded profit growth stood at 17% over 5 years and 11% on a TTM basis.
- Free Cash Flow increased to ₹611 crore in March 2020 from ₹504 crore in March 2019.
- Reserves grew to ₹2,410 crore in March 2020 from ₹1,987 crore in March 2019.
- Cash from Operating Activity increased to ₹626 crore in March 2020 from ₹499 crore in March 2019.

- Abbott India Ltd rises for third straight session
- What’s in a word? For India's FMCG brands, it's increasingly everything

### Bear Case

Abbott India's financial position shows an increase in borrowings from ₹0 in March 2019 to ₹175 crore in March 2020. Concurrently, fixed assets have more than doubled from ₹105 crore to ₹270 crore over the same period. While cash flow from operations increased to ₹626 crore in March 2020 from ₹499 crore in March 2019, cash used in investing activities also rose significantly to ₹401 crore from ₹257 crore. The company's net cash flow declined to ₹8 crore in March 2020 from ₹99 crore in the prior year. In terms of market performance, the stock has seen a decline of 15.44% over the last year, underperforming the Nifty Pharma index which jumped 18.39% and the Nifty which rose 7.58% in the same timeframe.

- Borrowings increased to ₹175 crore in March 2020 from ₹0 in March 2019.
- Fixed assets grew to ₹270 crore in March 2020 from ₹105 crore in March 2019.
- Net cash flow decreased to ₹8 crore in March 2020 from ₹99 crore in March 2019.
- The stock price has declined by 15.44% over the past year.

- Abbott India Ltd rises for third straight session
- What’s in a word? For India's FMCG brands, it's increasingly everything

### FAQs

**How has Abbott India's financial position changed between March 2019 and March 2020?**

Between March 2019 and March 2020, Abbott India's total assets increased from ₹2,941 crore to ₹3,547 crore. This growth was primarily driven by an increase in Fixed Assets, which rose from ₹105 crore to ₹270 crore, and Other Assets, which grew from ₹2,835 crore to ₹3,275 crore. Total liabilities also increased from ₹2,941 crore to ₹3,547 crore, with Borrowings appearing in March 2020 at ₹175 crore, compared to none in March 2019. Equity Capital remained stable at ₹21 crore, while Reserves increased from ₹1,987 crore to ₹2,410 crore.

**What has been Abbott India's cash flow performance in the fiscal years ending March 2019 and March 2020?**

In the fiscal year ending March 2020, Abbott India reported Cash from Operating Activity of ₹626 crore, an increase from ₹499 crore in March 2019. Free Cash Flow also improved to ₹611 crore in March 2020 from ₹504 crore in March 2019. However, Cash from Investing Activity increased significantly to a outflow of ₹401 crore in March 2020 from ₹257 crore in March 2019. Cash from Financing Activity also saw a larger outflow of ₹217 crore in March 2020 compared to ₹143 crore in March 2019. The Net Cash Flow for March 2020 was ₹8 crore, a decrease from ₹99 crore in March 2019.

**How has Abbott India's sales and profit growth trended over different periods?**

Abbott India has demonstrated a Compounded Sales Growth of 10% over the last 5 years and 6% on a Trailing Twelve Months (TTM) basis. For profit, the Compounded Profit Growth has been higher, at 17% over the last 5 years and 11% on a TTM basis.

**What is the current technical trend and key price levels for Abbott India?**

As of September 18, 2026, the daily trend for Abbott India is indicated as bullish with a Supertrend value of ₹25,215.03. The stock's closing price was ₹27,270.0. Key support levels are observed around ₹26,826.56 and ₹26,633.33, while resistance is noted near ₹28,521.55 and ₹29,900.95. However, the monthly trend is indicated as bearish with a Supertrend value of ₹35,106.85, and the weekly trend is also bearish with a Supertrend value of ₹28,649.94.

**What has been Abbott India's stock performance over the past year compared to market indices?**

In the past year, Abbott India's stock has decreased by 15.44%. This performance is compared to a 7.58% increase in the NIFTY index and an 18.39% increase in the Nifty Pharma index over the same period.

- Abbott India Ltd rises for third straight session
- What’s in a word? For India's FMCG brands, it's increasingly everything
## Technical analytics

- As of: 2026-09-18
- Daily trend: Weak Uptrend
- Weekly trend: Weak Uptrend
- Pivot point: ₹26,006.67
- Risk regime: Price Risk Requires Attention

### Support levels
- 26826.5625
- 25829.375
- 25670

### Resistance levels
- 28521.5515625
- 29900.95
- 30550.3251953125

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +5.25% |
| return_10 | +5.11% |
| return_1m | +2.60% |
| return_1y | -11.72% |
| return_20 | +4.40% |
| return_3m | +4.30% |
| return_5 | +7.96% |
| return_6m | +3.39% |
| return_since_start | -9.16% |
| return_ytd | -4.27% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -29.41% |
| annualized_volatility | +23.14% |

## Quarterly financials

Quarterly financials are not currently available.

## Official filings

No official filings are currently available.

## News and market events

- 2026-09-15 — BUSINESS: **Abbott India Ltd rises for third straight session** — Abbott India Ltd is quoting at Rs 26155, up 2.37% on the day as on 12:49 IST on the NSE. The stock is down 15.44% in last one year as compared to a 7.58% jump in NIFTY and a 18.39% jump in the Nifty Pharma index. — [Source](https://www.business-standard.com/markets/capital-market-news/abbott-india-ltd-rises-for-third-straight-session-126091500481_1.html)
- 2026-09-14 — Economic Times: **What’s in a word? For India's FMCG brands, it's increasingly everything** — Indian regulators are intensifying scrutiny over misleading food product claims. Companies now face legal challenges for unsubstantiated marketing statements. New front-of-pack warning labels are proposed for unhealthy packaged foods. This regulatory push aims to provide consumers with clearer product information. Companies are consequently allocating more resources towards compliance and quality checks. — [Source](https://economictimes.indiatimes.com/industry/cons-products/food/fssai-crackdown-on-misleading-food-claims-fmcg-companies-face-scrutiny/articleshow/134234919.cms)
- 2026-08-12 — CNBC-TV18: **Stocks to Watch for August 13: Tata Motors, Apollo Hospitals, UltraTech Cement, Lenskart and more** — Stocks of Astral, Lenskart, Tata Motors, IRCON and other companies will be in focus on Wednesday as these companies reported their June quarter earnings after market hours on Tuesday. Investors will also watch Asian Energy Services, Awfis Space Solutions, Balaji Telefilms and others, which are scheduled to announce their results tomorrow. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-august-13-tata-motors-ircon-astral-lenskart-and-more-19967707.htm)
- 2026-08-12 — CNBC-TV18: **Q1 Results Live Updates: Ircon International profit down 43%, Astral EBITDA up 23%** — Q1 Results LIVE Updates: Apollo Hospitals and Grasim are among the final Nifty 50 names that will be reporting their results today along with broader market names such as HAL, IRCTC, IRCON, Lenskart, Astral, Tata Motors CV, among others. Manappuram, PI Industries, Bata India, Senco Gold, and others will also be reacting to their results. Watch this space for all the LIVE Q1 result updates. — [Source](https://www.cnbctv18.com/market/q1-results-live-updates-today-hal-apollo-hosp-manappuram-irctc-ircon-lenskart-grasim-pi-ind-astral-share-price-liveblog-19967133.htm)
- 2026-07-24 — Mint: **Trump's tariff policy: Abbott India, Ajanta Pharma to Alembic — pharma stocks crash up to 4%** — Pharma stocks dipped on July 24 after President Trump announced a phased tariff plan for imported generic medicines, raising concerns for Indian exporters. Abbott India led losses at 3.69%, prompting fears over the future of American production and long-term impacts on stocks. — [Source](https://www.livemint.com/market/stock-market-news/trumps-tariff-policy-abbott-india-ajanta-pharma-to-alembic-pharma-stocks-crash-up-to-4-11784869745089.html)
- 2026-07-23 — Economic Times: **Dividend alert! Last day to buy Bharti Airtel, Hero MotoCorp, among 43 stocks for dividend payout worth Rs 1,127** — As per Sebi's T+1 settlement cycle, investors must buy a company's shares at least one trading day before the record date to ensure the shares are credited to their demat accounts in time, and they become eligible for the corporate action — [Source](https://economictimes.indiatimes.com/markets/stocks/news/dividend-alert-last-day-to-buy-bharti-airtel-hero-motocorp-among-43-stocks-for-dividend-payout-worth-rs-1127/articleshow/132570497.cms)
- 2026-07-22 — The Hindu: **US tariff threat drags Nifty Pharma 1.4% lower; Lupin, Auropharma lead decline** — US tariff threats lead to a 1.4% drop in Nifty Pharma, with Lupin and Auropharma experiencing significant declines. — [Source](https://www.thehindubusinessline.com/markets/stock-markets/us-tariff-threat-drags-nifty-pharma-14-lower-lupin-auropharma-lead-decline/article71252663.ece)
- 2026-07-22 — News18: **Lupin, Aurobindo, Cipla Fall Up To 2.9%: Pharma Stocks Under Pressure As Trump's Tariff Roadmap Rattles Sentiment** — Lupin falls 2.88%, Aurobindo Pharma declines 2.73%, Alkem Laboratories slips 2.44%, Zydus Lifesciences drops 2.20%, while Cipla slips 2.09%. — [Source](https://www.news18.com/business/markets/lupin-aurobindo-cipla-fall-up-to-2-9-pharma-stocks-under-pressure-as-trumps-tariff-roadmap-rattles-sentiment-ws-l-10226502.html)
- 2026-07-19 — Economic Times: **Bonus, dividends and stock splits: Bharti Airtel, Hero MotoCorp among 88 stocks turning ex-date this week. Do you own any?** — Investors must hold shares in their demat accounts on the respective record dates to be eligible. Here is the complete day-wise list of key corporate actions to track. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/bonus-dividends-and-stock-splits-bharti-airtel-hero-motocorp-among-88-stocks-turning-ex-date-this-week-do-you-own-any/articleshow/132491671.cms)

## Business profile

**Strategic vision:** Develops, manufactures, and markets branded generic medicines in India.

### Business segments
- **Primary Care:** Focuses on general medicine, including pain management, gastroenterology, and anti-infectives.
- **Specialty Care – Metabolics & Urology:** Focuses on therapies for thyroid disorders, diabetes care, weight management, and urological health.
- **Specialty Care – Neuroscience:** Manages a specialized portfolio of psychiatric and neurological treatments.
- **Hospital Care:** Focuses on specialized formulations for anesthesiology and neonatology utilized within hospital settings.

### Competitive strengths
- Focus on branded generic medicines tailored to the domestic healthcare market.
- Extensive nationwide distribution network.
- Specialized divisions targeting distinct therapeutic areas.

## Related stocks

- [ACUTAAS (Healthcare)](https://faxioms.com/stocks/acutaas) — +3.86%
- [AJANTPHARM (Healthcare)](https://faxioms.com/stocks/ajantpharm) — +1.61%
- [ALKEM (Healthcare)](https://faxioms.com/stocks/alkem) — +0.14%
- [ANTHEM (Healthcare)](https://faxioms.com/stocks/anthem) — -0.35%
- [ASTERDM (Healthcare)](https://faxioms.com/stocks/asterdm) — -0.85%

## Freshness and sources

- Data as of: 2026-09-18
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/abbotindia
Markdown representation: https://faxioms.com/stocks/abbotindia?render=md